Trial Profile
Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Crenolanib (Primary) ; Azacitidine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin; Mitoxantrone
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors AROG Pharmaceuticals
- 17 Jul 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 16 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Apr 2020.